Oncolytics Biotech Inc expected to post a loss of 11 cents a share - Earnings Preview
Oncolytics Biotech Inc
ONC is expected to show no change in quarterly revenue when it reports results on August 8 for the period ending June 30 2025LSEG's mean analyst estimate for Oncolytics Biotech Inc is for a loss of 11 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Previous quarterly performance (using preferred earnings measure in Canadian dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Mar. 31 2025 | -0.09 | -0.10 | -0.08 | Beat | 20 |
Dec. 31 2025 | -0.13 | -0.12 | -0.10 | Beat | 18.2 |
Sep. 30 2024 | -0.10 | -0.10 | -0.12 | Missed | -17.8 |
Jun. 30 2024 | -0.10 | -0.10 | -0.10 | Met | 0.6 |
Mar. 31 2024 | -0.11 | -0.11 | -0.09 | Beat | 16.3 |
Dec. 31 2023 | -0.15 | -0.15 | -0.05 | Beat | 66.1 |
Sep. 30 2023 | -0.10 | -0.10 | -0.14 | Missed | -34.6 |
Jun. 30 2023 | -0.11 | -0.11 | -0.12 | Missed | -6.3 |
This summary was machine generated August 6 at 12:52 GMT. All figures in Canadian dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
